Autoimmune Biomarkers, Antibodies, and Immunologic Evaluation of the Patient with Fibrotic Lung Disease - 01/08/19
Doi : 10.1016/j.ccm.2019.06.002
Argyris Tzouvelekis, MD, MSc, PhD a, Theodoros Karampitsakos, MD, MSc a, Evangelos Bouros, MSc, PhD a, Vassilios Tzilas, MD, PhD a, Stamatis-Nick Liossis, MD, PhD b, Demosthenes Bouros, MD, PhD, FERS, FCCP, FAPSR a, ⁎ 
a 1st Academic Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens, Hospital for Diseases of the Chest, “Sotiria”, Mesogion 152, Athens 11527, Greece
b Division of Rheumatology, Department of Internal Medicine, Patras University Hospital, University of Patras Medical School, Patras, Rio 26504, Greece
∗Corresponding author.
Résumé |
This review summarizes the current state of knowledge on experimental and clinical biomarkers of autoimmunity and aims to highlight important aspects of the immunologic evaluation of a patient with fibrotic lung disease.
Le texte complet de cet article est disponible en PDF.Keywords : Autoimmunity, Interstitial lung diseases, Connective tissue disorders, Chronic lung injury, Biomarkers
Plan
| Disclosure Statement: None to declare. |
|
| Conflicts of Interest: None to declare. |
© 2019
Elsevier Inc. Tous droits réservés.
Vol 40 - N° 3
P. 679-691 - septembre 2019 Retour au numéro
Article précédent
- Pulmonary Pathology in Rheumatic Disease
- Andrea V. Arrossi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?